These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2126668)

  • 1. A thymosin-tuftsin conjugate as a new potential immunomodulator in cattle.
    Khansari DN; Jafari P
    Adv Vet Sci Comp Med; 1990; 35():161-77. PubMed ID: 2126668
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis.
    Owais M; Misra-Bhattacharya S; Haq W; Gupta CM
    J Drug Target; 2003 May; 11(4):247-51. PubMed ID: 14578113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tuftsin--endogenous immunomodulator].
    Dzierzbicka K; Rakowski T; Kołodziejczyk AM
    Postepy Biochem; 2000; 46(4):327-35. PubMed ID: 11449967
    [No Abstract]   [Full Text] [Related]  

  • 4. Tuftsin: a naturally occurring immunopotentiating factor. I. In vitro enhancement of murine natural cell-mediated cytotoxicity.
    Phillips JH; Babcock GF; Nishioka K
    J Immunol; 1981 Mar; 126(3):915-21. PubMed ID: 6893996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunostimulants--therapeutic aspects].
    Diezel W; Volk HD; Daniel V; Gruner S; Sönnichsen N
    Arch Geschwulstforsch; 1989; 59(1):45-51. PubMed ID: 2493778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal influences on the reticuloendothelial system: current status of the role of thymosin in the regulation and modulation of immunity.
    Goldstein AL; Thurman GB; Low TL; Rossio JL; Trivers GE
    J Reticuloendothel Soc; 1978 Apr; 23(4):253-66. PubMed ID: 353275
    [No Abstract]   [Full Text] [Related]  

  • 7. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
    Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
    Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors.
    An Y; Li L; Yang D; Jia N; Xu C; Wang Q; Wang S; Yuan S
    Anticancer Drugs; 2014 Sep; 25(8):857-67. PubMed ID: 24714081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin: an immunomodulator of antibody production in man.
    Górski A; Korczak-Kowalska G; Nowaczyk M; Gaciong Z; Skopińska-Rózewska E
    Immunology; 1982 Nov; 47(3):497-501. PubMed ID: 6215339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infection prophylaxis in the calf-fattening operation].
    Mayr B
    Tierarztl Prax; 1991 Apr; 19(2):124-6. PubMed ID: 1906201
    [No Abstract]   [Full Text] [Related]  

  • 11. The biological activity of new tuftsin derivatives--induction of phagocytosis.
    Wardowska A; Dzierzbicka K; Trzonkowski P; Myśliwski A
    Acta Pol Pharm; 2006; 63(5):378-81. PubMed ID: 17357588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tuftsin--new analogues and properties].
    Wardowska A; Dzierzbicka K; Myśliwski A
    Postepy Biochem; 2007; 53(1):60-5. PubMed ID: 17718389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new immunologic stimulant].
    Med Klin; 1978 Oct; 73(43):2-3. PubMed ID: 309552
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice.
    Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prophylactic potential of an immunomodulator against respiratory disease in calves.
    Larsson B; Fossum C; Törnquist M; Matsson P; Alenius S
    Acta Vet Scand; 1985; 26(2):262-72. PubMed ID: 2998168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvant administration on weight gain, infectious diseases, and mortality of veal calves.
    Vandenbossche GM; Vermeersch H; Embrechts E; Theys H; Baeck N; Remon JP
    Vet Q; 1994 Dec; 16(4):226-8. PubMed ID: 7740748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunostimulant therapy of kidney diseases].
    Karastanev I
    Vutr Boles; 1982; 21(3):8-13. PubMed ID: 6180558
    [No Abstract]   [Full Text] [Related]  

  • 19. Interactions of radiolabeled tuftsin with human neutrophils.
    Nair RM; Ponce B; Fudenberg HH
    Immunochemistry; 1978 Dec; 15(12):901-7. PubMed ID: 582033
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological approaches to the breakdown of hepatitis B viral persistence.
    Lau GK; Wang B; Carman W
    Chin Med J (Engl); 1998 Jun; 111(6):560-4. PubMed ID: 11245080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.